Skip to main content

Ossabaw Pigs With a PCSK9 Gain-of-Function Mutation Develop Accelerated Coronary Atherosclerotic Lesions: A Novel Model for Preclinical Studies.

Citation
Yuan, F., et al. “Ossabaw Pigs With A Pcsk9 Gain-Of-Function Mutation Develop Accelerated Coronary Atherosclerotic Lesions: A Novel Model For Preclinical Studies.”. Journal Of The American Heart Association.
Center Indiana University
Author Fang Yuan, Liang Guo, Kyoung-Ha Park, John R Woollard, Kwon Taek-Geun, Kai Jiang, Tamene Melkamu, Bin Zang, Samantha L Smith, Scott C Fahrenkrug, Frank D Kolodgie, Amir Lerman, Renu Virmani, Lilach O Lerman, Daniel F Carlson
Keywords PCSK9, atherosclerosis, coronary artery disease, Pig
Abstract

BACKGROUND: Ossabaw pigs are unique miniature swine with genetic predisposition to develop metabolic syndrome and coronary atherosclerosis after extended periods receiving atherogenic diets. We have hypothesized that transgenic Ossabaw swine expressing chimp (proprotein convertase subtilisin-like/kexin type 9) containing the D374Y gain of function would develop familial hypercholesterolemia and coronary artery plaques more rapidly than Landrace swine with the same transgene.

METHODS AND RESULTS: Ossabaw and Landrace gain-of-function founders were generated by transposition and cloning. Histopathologic findings in the Ossabaw founder animal showed more advanced plaques and higher stenosis than in the Landrace founder, underscoring the Ossabaw genetic predisposition to atherosclerosis. We chose to further characterize the Ossabaw gain-of-function animals receiving standard or atherogenic diets in a 6-month longitudinal study using computed tomography, magnetic resonance (MR) imaging, intravascular ultrasound, and optical coherence tomography, followed by pathological analysis of atherosclerosis focused on the coronary arteries. The Ossabaw model was consistently hypercholesterolemic, with or without dietary challenge, and by 6 months had consistent and diffuse fibrofatty or fibroatheromatous plaques with necrosis, overlying fibrous caps, and calcification in up to 10% of coronary plaques.

CONCLUSIONS: The Ossabaw gain-of-function model provides consistent and robust disease development in a time frame that is practical for use in preclinical therapeutic evaluation to drive innovation. Although no animal model perfectly mimics the human condition, this genetic large-animal model is a novel tool for testing therapeutic interventions in the context of developing and advanced coronary artery disease.

Year of Publication
2018
Journal
Journal of the American Heart Association
Volume
7
Issue
6
Date Published
12/2018
ISSN Number
2047-9980
DOI
10.1161/JAHA.117.006207
Alternate Journal
J Am Heart Assoc
PMID
29572319
PMCID
PMC5907533
Download citation